Karen Chu, MD
Obstetrics/Gynecology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Office
- 1
- Since medical school
- 27 years
- State University of New York Downstate Medical Center, 1999
Offices
1 location · Regents Univ of California UCSF · 276 clinicians in this group
Looking this up.
Hospitals listed: California Pacific Medical Center- Van Ness Campus. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chu’s office at (415) 476-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A84215 · Current
Licensed to practise in California · since 2003 · expires 2027-01-31 · State University of New York Health Science Center at Brooklyn.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$9,454
Medicare paid this office $9,454 for 50 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 28 | $5,316 | $108 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 16 | $908 | $57 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 17 | $806 | $47 |
Who their Medicare patients are
50 Original Medicare patients in 2024. Average age 71 · Women 100% · Also on Medicaid 22% · Health risk score 0.75. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 56%.
The office billed $23,330, Medicare allowed $12,596 and paid $9,454; for 110 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 50 | 110 | 71 | 0.75 | $23,330 | $9,454 |
| 2023 | 46 | 107 | 72 | 0.58 | $25,919 | $8,624 |
| 2022 | 36 | 59 | 71 | 0.72 | $13,785 | $4,787 |
| 2021 | 30 | 51 | 70 | 0.61 | $8,975 | $3,927 |
| 2020 | 21 | 47 | 68 | 0.74 | $10,706 | $3,800 |
| 2019 | 25 | 54 | 72 | 0.88 | $12,104 | $4,101 |
| 2018 | 19 | 28 | 73 | 0.95 | $7,745 | $1,851 |
| 2017 | 19 | 31 | 72 | 0.95 | $8,355 | $2,129 |
| 2016 | 11 | 27 | 68 | 0.94 | $5,125 | $1,881 |
| 2015 | 18 | 39 | 69 | 1.19 | $8,495 | $3,547 |
| 2014 | 19 | 39 | 69 | 0.77 | $10,215 | $2,744 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Return visit (30+ min) | 18 | $3,943 | $113 |
| New patient visit (30+ min) | 12 | $1,050 | $87 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 22 | $1,031 | $47 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 12 | $656 | $55 |
2022: 2 services
| Return visit (30+ min) | 15 | $1,915 | $120 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 12 | $557 | $46 |
2021: 1 service
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 11 | $518 | $47 |
2019: 1 service
| Short return visit (20+ min) | 12 | $1,009 | $59 |
Drugs they prescribed that Part D paid
$29,106
Pharmacies billed $29,106 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
137 generic and 35 brand-name prescriptions · $29,106 in drug cost · 23 antibiotic prescriptions to 13 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estring | 13 | $6,794 | $523 |
| Estradiol | 31 | $2,905 | $94 |
| Alendronate | 12 | $86 | $7 |
| Triamcinolone Acetonide | 21 | $47 | $2 |
Year by year
| 2024 | 172 | 81 | None | 20% | $29,106 |
| 2023 | 120 | 63 | 0% (0) | 22% | $20,235 |
| 2022 | 124 | 60 | None | 23% | $17,124 |
| 2021 | 90 | 41 | 0% (0) | 26% | $13,508 |
| 2020 | 63 | 25 | 0% (0) | 24% | $9,788 |
| 2019 | 67 | 31 | 0% (0) | 18% | $7,179 |
| 2018 | 62 | 20 | 0% (0) | 23% | $6,781 |
| 2017 | 44 | 15 | 0% (0) | 41% | $7,577 |
| 2016 | 48 | 15 | 0% (0) | 40% | $5,859 |
| 2015 | 47 | 22 | 0% (0) | 34% | $5,560 |
| 2014 | 46 | 17 | 0% (0) | 28% | $4,934 |
| 2013 | 53 | 21 | None | 60% | $8,731 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Estradiol | 23 | $3,266 | $142 |
| Triamcinolone Acetonide | 12 | $38 | $3 |
2022: 1 drug
| Estradiol | 12 | $1,939 | $162 |
2021: 2 drugs
| Estradiol | 14 | $2,013 | $144 |
| Valacyclovir | 12 | $364 | $30 |
2020: 1 drug
| Estradiol | 19 | $4,276 | $225 |
2018: 1 drug
| Yuvafem | 14 | $1,909 | $136 |
2017: 1 drug
| Yuvafem | 13 | $2,263 | $174 |
2013: 1 drug
| Prempro | 12 | $1,715 | $143 |
Money from drug and device companies
$308 in 2025
| 2025 | 10 | 13 | None | $308 |
| 2024 | 7 | 11 | None | $269 |
| 2023 | 10 | 17 | None | $515 |
| 2022 | 9 | 25 | None | $669 |
| 2021 | 9 | 39 | None | $805 |
| 2020 | 8 | 39 | None | $744 |
| 2019 | 9 | 22 | None | $654 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Astellas Pharma US | Veozah | $81 | 3 payments
|
| Millicent US | Femring | $38 | 2 payments
|
| CooperSurgical | None | $31 | 1 payment
|
| Shield Therapeutics | Accrufer | $27 | 1 payment
|
| Vertex Pharmaceuticals | Journavx | $27 | 1 payment
|
| Biogen | Zurzuvae | $25 | 1 payment
|
See all 13 published payments
| Bayer Healthcare Pharmaceuticals | Meals · 2025-11-26 | Lynkuet | $23 |
| Octapharma USA | Meals · 2025-11-24 | Fibryga | $20 |
| Biogen | Meals · 2025-10-16 | Zurzuvae | $25 |
| CooperSurgical | Meals · 2025-09-19 | None | $31 |
| Shield Therapeutics | Meals · 2025-08-19 | Accrufer | $27 |
| Exact Sciences | Meals · 2025-07-29 | Cologuard Collection Kit | $23 |
| Vertex Pharmaceuticals | Meals · 2025-06-02 | Journavx | $27 |
| Millicent US | Meals · 2025-05-30 | Femlyv | $17 |
| Millicent US | Meals · 2025-04-15 | Femring | $21 |
| Astellas Pharma US | Meals · 2025-03-24 | Veozah | $32 |
| Astellas Pharma US | Meals · 2025-02-26 | Veozah | $23 |
| Astellas Pharma US | Meals · 2025-02-03 | Veozah | $26 |
| Meditrina | Meals · 2025-01-23 | None | $13 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $269
| Astellas Pharma US | Veozah | $118 | 2 payments
|
| Biogen | None | $50 | 2 payments
|
| Mayne Pharma Commercial | None | $29 | 3 payments
|
| Ethicon US | Megadyne | $20 | 1 payment
|
| Minerva Surgical | None | $19 | 1 payment
|
| Organon | Jada System | $17 | 1 payment
|
| Millicent US | Femring | $17 | 1 payment
|
2023: $515
| Ethicon US | Harmonic | $203 | 4 payments
|
| Amgen | Evenity | $92 | 3 payments
|
| Mayne Pharma Commercial | None | $46 | 3 payments
|
| Shield Therapeutics | Accrufer | $34 | 1 payment
|
| Medicem | Dilapan-S | $29 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Kyleena | $25 | 1 payment
|
| Ascend Therapeutics US | Estrogel | $25 | 1 payment
|
| Sumitomo Pharma America | Myfembree | $23 | 1 payment
|
| Astellas Pharma US | Veozah | $21 | 1 payment
|
| CooperSurgical | Paragard T 380a | $16 | 1 payment
|
2022: $669
| Amgen | Prolia | $233 | 7 payments
|
| Abbvie | Oriahnn | $176 | 8 payments
|
| Bayer HealthCare Pharmaceuticals | Kyleena | $58 | 2 payments
|
| Myovant Sciences | Myfembree | $53 | 2 payments
|
| Mayne Pharma | None | $51 | 2 payments
|
| Ethicon US | Stratafix | $29 | 1 payment
|
| TherapeuticsMD | Annovera | $25 | 1 payment
|
| Hologic | Acessa Provu System | $23 | 1 payment
|
| Agile Therapeutics | Twirla | $22 | 1 payment
|
2021: $805
| AbbVie | Lo Loestrin Fe | $161 | 7 payments
|
| Applied Medical Resources | Gelpoint V-Path | $145 | 2 payments
|
| Amgen | Evenity | $137 | 6 payments
|
| Avion Pharmaceuticals | Balcoltra | $137 | 14 payments
|
| Myovant Sciences | Myfembree | $124 | 5 payments
|
| Mylan Pharmaceuticals | Xulane | $40 | 2 payments
|
| TherapeuticsMD | Annovera | $22 | 1 payment
|
| Merck Sharp & Dohme | Nexplanon | $21 | 1 payment
|
| Organon | Nexplanon | $18 | 1 payment
|
2020: $744
| TherapeuticsMD | Annovera | $172 | 11 payments
|
| AbbVie | Orilissa | $172 | 8 payments
|
| Bayer HealthCare Pharmaceuticals | Kyleena | $115 | 6 payments
|
| Amgen | Evenity | $100 | 4 payments
|
| Avion Pharmaceuticals | Balcoltra | $77 | 5 payments
|
| Mylan Pharmaceuticals | Xulane | $43 | 2 payments
|
| CooperSurgical | Paragard | $42 | 2 payments
|
| AMAG Pharmaceuticals | Vyleesi | $23 | 1 payment
|
2019: $654
| Amgen | Evenity | $271 | 7 payments
|
| AbbVie | Orilissa | $113 | 6 payments
|
| TherapeuticsMD | Imvexxy | $88 | 3 payments
|
| Ethicon US | Surgicel Powder | $87 | 1 payment
|
| AMAG Pharmaceuticals | Vyleesi | $25 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kyleena | $20 | 1 payment
|
| Exeltis USA | Vitafol Ultra | $20 | 1 payment
|
| Merck Sharp & Dohme | Nexplanon | $16 | 1 payment
|
| Avion Pharmaceuticals | Prenate Mini | $14 | 1 payment
|
Professional record
- NPI
- 1053436899
- Licence
- CA A84215California A84215: Current · expires 2027-01-31
- Trained
- State University of New York Downstate Medical Center, 1999 · 27 years ago
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 1 Daniel Burnham Ct Ste 230c, San Francisco, CA, 94109
- NPI first listed
- 2007-03-20
- NPI last updated
- 2018-04-09
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 3838 California St Rm 412, San Francisco, CA, 94118